For Providers

How can 24-chromosome PGS help my patients?

Preimplantation Genetic Screening (PGS) for chromosomal aneuploidies in conjunction with an In Vitro Fertilization (IVF) cycle will improve your patient's chances of a healthy and successful transfer, and subsequent pregnancy, by:

  • Increasing implantation rates
  • Reducing the likelihood of miscarriage
  • Reducing the risk of pregnancies with chromosomal abnormalities
  • Identifying euploid embryos for Single Embryo Transfer (SET), to avoid the risks associated with transferring multiple embryos.

RGI offers the latest in 24-chromosome PGS technologies, utilizing Next-Generation Sequencing (NGS) and array Comparative Genomic Hybridization (aCGH). Give your patients the advantage of comprehensive knowledge by choosing PGS for chromosomal abnormalities with RGI.

Nearly half of all in-vitro embryos have chromosomal abnormalities.1 All couples are at risk for aneuploidy, regardless of pregnancy history. Moreover, aneuploidy rates increase with maternal age from approximately 30% at age 35, to 85% at age 42.

24-chromosome PGS is performed on Day 5/6 blastocyst biopsies, with embryo cryopreservation, and a future frozen embryo transfer (FET). Biopsied samples are analyzed in RGI's CAP, CLIA and NY State certified laboratory. Results can be expected within 7-10 business days.

Patients with any of the following indications may benefit from RGI's 24-chromosome PGS:

  • Advanced maternal age (AMA)
  • Repeated IVF failures
  • Recurrent pregnancy loss (RPL)
  • Prior pregnancy or child with a chromosomal abnormality
  • Patient desire to determine sex of the embryo
  • Maximizing a donor cycle
  • Testing previously frozen embryos
  • Decreasing chances of a chromosome abnormality in a pregnancy
  • Combined with testing for single gene condition(s)

Read more about PGS options here or refer a patient to RGI


1. [Yang et al., Molecular Cytogenetics 2012, 5:24]
_